The Oncology R&D Unit of GlaxoSmithKline (GSK) has entered into a new research alliance agreement with US Oncology, Inc., a nationwide cancer care company supporting the largest community-based research network specializing in Phase I-IV oncology clinical trials in the United States. The collaboration, announced today, is aimed at enhancing the quality and improving the execution time of some of GSK’s most important clinical trials.
Under the agreement, scientists and oncologists within US Oncology will provide real, patient-oriented insight to clinical researchers at GSK. US Oncology researchers will also have an opportunity to critique the design of future cancer trials. The collective feedback will be used to better develop cancer trials that will directly address some of the most pressing patient needs.
“We have no doubt that this alliance agreement with US Oncology will help us advance clinical research,” said Jeffrey Bloss, M.D., Vice President of U.S. Clinical Development and Medical Affairs at GSK Oncology. “By sharing some of our research efforts with the nation’s largest network of leading physicians and scientists, we hope to improve trial design, and potentially, enrollment. Ultimately, our collective goal is to find answers more quickly for patients, and to design trials and studies in a manner that hopefully will bring maximum benefit to them.”
The US Oncology network currently consists of over 1,300 physicians with more than half participating in clinical research. US Oncology investigators have conducted over 650 trials over the last 10 years and have enrolled over 38,500 patients to clinical trials. The network of oncologists at US Oncology sees, on average, more than 50,000 patients each month. Via the scope of the network, patients have access to the latest clinical research and treatment options. US Oncology hopes to take those insights from the treatment room back to the laboratory where future medicines are being developed.
“In the emerging era of personalized medicine, we are pleased to announce our strategic alliance with GSK where both GSK and US Oncology have an equal commitment to streamlining the clinical development process and matching the right patient to the right trial at the right time,” said Steve Smith, vice president and general manager of Research and Personalized Science at US Oncology. “We are enthusiastic about this new strategic alliance agreement with GSK, and about this opportunity to advance potential life saving and life enhancing cancer therapies by working closely with a leading innovator.”
GSK in Oncology
GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary 'bench to bedside' approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer from all sides with a new generation of patient-focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
About US Oncology Research
With experienced investigators and dedicated research nurses, US Oncology Research represents the largest research network specializing in Phase I-IV oncology clinical trials in the United States. US Oncology Research serves more than 80 sites in 200 locations with over 70 open trials being managed at any given time.
The US Oncology Research network has accrued more than 38,500 patients since its inception and has contributed to the development of 36 of the latest cancer-fighting drugs approved by the FDA. For more information, visit the "US Oncology Research" section under "About US Oncology" on the company's Web site, www.usoncology.com.
Enquiries:
UK Media enquiries: Philip Thomson (020) 8047 5502
David Outhwaite (020) 8047 5502
Stephen Rea (020) 8047 5502
US Media enquiries: Nancy Pekarek (919) 483 2839
Mary Anne Rhyne (919) 483 2839
Kevin Colgan (919) 483 2839
Lisa Behrens (919) 483 2697
European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564
Sally Ferguson (020) 8047 5543
Gary Davies (020) 8047 5503
US Analyst/ Investor enquiries: Tom Curry (215) 751 5419
Jen Hill Baxter (215) 751 7002
# # #
|
International Stem Cell Corporation Announces Collaboration with Scripps Research Institute’s Center for Regenerative Medicine to Study Parthenogenetic Stem Cells 
